Intangible Assets

Tarsus appears to rely on regulated pharmaceutical IP and product-specific exclusivity, which can support pricing power versus generic peers while the patent/exclusivity window lasts.

Compared with broader biotech peers, the moat is narrower because it is concentrated in a small number of assets rather than a diversified portfolio of durable brands or platform IP.

The company’s filings-based moat is more durable than a pure commodity drug seller, but it is less entrenched than peers with multiple late-stage assets or established chronic-care franchises.

Intangible assets likely matter most through regulatory barriers and clinical data exclusivity, which can preserve margins for a period but do not by themselves create permanent peer dependence.

Switching Costs

Tarsus does not appear to benefit from high switching costs because prescribing decisions in its markets are typically driven by physician choice, payer access, and clinical differentiation rather than customer lock-in.

Compared with software-like or device-embedded peers, patients and prescribers can shift to alternative therapies if efficacy, access, or reimbursement changes.

Any retention advantage is product-specific and temporary, so it does not translate into durable switching friction across the franchise.

The company’s negative TTM ROIC is consistent with a business that has not yet converted product adoption into a structurally sticky economic relationship.

Network Effects

Tarsus does not exhibit meaningful network effects because demand for its therapies does not become more valuable as more users adopt the product.

Unlike platform or data-network businesses, one prescriber’s use does not materially increase another prescriber’s willingness to use the therapy.

Peer comparison is unfavorable because most biopharma companies also lack network effects, so this is not a differentiating moat source for Tarsus.

There is no evidence that ecosystem participation or user density creates self-reinforcing retention or pricing power.

Cost Advantage

Tarsus does not appear to have a durable cost advantage because specialty drug development and commercialization are not structurally lower-cost than peers on a sustained basis.

Its negative ROIC and negative capital efficiency imply that current economics are not yet translating into a repeatable cost edge versus better-scaled competitors.

Compared with large-cap pharma peers, Tarsus likely faces higher per-unit overhead and less procurement leverage, which limits margin durability.

Any manufacturing or commercialization efficiencies are not visible as a persistent peer advantage in the provided metrics.

Efficient Scale

Tarsus may benefit from some efficient-scale characteristics if its addressable niche is narrow enough that a small number of specialized products can support meaningful share, but that advantage is not yet clearly dominant.

Compared with large diversified pharma peers, the company lacks the scale to make its fixed-cost base a strong barrier to entry.

The negative TTM ROIC suggests the current scale is not yet producing the kind of operating leverage that would materially deter competitors.

Efficient scale is more plausible in a focused specialty niche than in broad therapeutic categories, but the evidence does not support a strong structural barrier.

Overall Score

Tarsus shows some temporary protection from product-specific regulatory and IP barriers, but its moat is not broad or deeply entrenched versus peers because switching costs, network effects, and cost advantages are weak and current capital returns remain negative.